Sleep Disorders/Aging
Conditions
Interventions
Control group:Take a placebo capsule (containing 500 mg of corn starch) once daily after breakfast for a total of 12 weeks.
UA group:Take a intervention capsule (containing 500 mg of Urolithin A) once daily after breakfast for a total of 12 weeks.
Fisetin group:Take a intervention capsule (containing 500 mg of Fisetin) once daily after breakfast for a total of 12 weeks.
UA+Fisetin group:Take a intervention capsule (containing 300 mg of Urolithin A + 200 mg of Fisetin) once daily after breakfast for a total of 12 weeks.
Sponsors
Wuhan Wuchang Hospital
Eligibility
Sex/Gender
All
Age
45 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. Aged 45-70 years; 2. Total score > 5 points on the Pittsburgh Sleep Quality Index (PSQI) for sleep quality assessment; 3. Able to use personal mobile devices for WeChat, internet access, and related operations; 4. Informed about the intervention trial and willing to undergo sleep monitoring and other examinations during the study; 5. Commitment to consume coffee, strong tea, or alcohol <=1 time per week during the trial period.
Exclusion criteria
Exclusion criteria: 1. Participation in any clinical trials or dietary/exercise intervention programs within the past 3 months or concurrently; 2. Diagnosis of major mental disorders or family history thereof, or current use of psychotropic drugs or mood-regulating medications; 3. Experiencing major psychological trauma (e.g., death of a close relative, significant financial loss) personally or within the family in the past 3 months; 4. Severe diseases affecting inflammatory levels and/or endocrine components (e.g., severe obesity, uncontrolled diabetes or poorly controlled blood glucose, myocardial infarction, cerebral infarction); 5. Current use of hormonal medications, beta-blockers, steroids, non-steroidal anti-inflammatory drugs (NSAIDs), etc.; 6. Use of medications potentially affecting sleep or aging biomarkers (e.g., melatonin, antidepressants, anxiolytics) within the past 3 months; 7. Plans for relocation or long-term travel within the next 6 months, which may hinder continuous intervention and follow-up.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Sleep quality;Chronotype;Daytime Vigilance;Objective sleep parameters;Polysomnography;Frailty Assessment; | — |
Secondary
| Measure | Time frame |
|---|---|
| Blood Biochemistry and Metabolic Markers;Liver Function;Thyroid Function Panel (TSH, TT3, TT4, FT3, FT4);Aging Biomarkers;Renal Function;Inflammatory Factors;Oxidative Stress;Immunological Index;Cortisol;nicotinamide adenine dinucleotide, NAD;Fatigue and Energy Assessment;Depression and Anxiety Assessment;Quality of Life Assessment;Circadian Rhythm-Related Proteins;Gut Microbiota Analysis;Skin Condition Rating Score;Hair Health Score;Nail Assessment; | — |
Countries
China
Contacts
Public ContactHui Xiong
Wuhan Wuchang Hospital
Outcome results
None listed